


EDE Dengue monoclonal antibodies

Clinical ready human monoclonal antibodies that target the Envelope Dimer Epitope on dengue virions, enabling cross-serotype neutralisation from a single conserved site and deployable IgG/fragment formats for passive immunisation.

Applications: Post-exposure therapy, Pre-exposure prophylaxis, Outbreak ring prophylaxis, High-risk healthcare exposure, Serotype-agnostic treatment, Reference assay standards, Emergency stockpiles



Features	Benefits
Demonstrated broad neutralisation of dengue virions produced in insect and human cells	Single-antibody approach supports cross-serotype coverage
Two antibody classes (EDE1/EDE2) with distinct breadth profiles characterised in vitro	Streamlines development by focusing on a conserved dimer epitope
Reported therapeutic activity of EDE antibodies against Zika in preclinical studies	Suitable for prophylactic or therapeutic passive immunization use cases

Features	Benefits
Compatible with multiple molecular formats (full IgG and fragments)	Enables consistent antigen/assay alignment around the E-dimer epitope
Epitope definition and assays anchored to native virion quaternary structure	Supported by breadth across diverse clinical strains in cell-based assays
Binds a quaternary epitope spanning the E-protein dimer interface across DENV-1-4	Potential spill over utility against related flaviviruses (e.g., Zika)
Clinical-ready asset with first-in-human trial planned	

Patented and Available for

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.